Press releases

Chordate Medical Holding AB's (publ) ("Chordate") has today procured bridge loans of SEK 7,125 million, in five different agreements, from...
Clinics in Malmö and Solna in Sweden have now started treating migraine patients with Chordate Medical Holding AB's (publ) ("Chordate")...
Chordate Medical Holding AB (publ) ("Chordate") has received a prepaid order for two new generation K.O.S machines, for immediate delivery to...
Chordate Medical Holding AB's (publ) ("Chordate") treatment has now been approved in a clinical evaluation at three major hospitals in Saudi...
Chordate Medical Holding AB (publ) ("the company, or "Chordate") is a Swedish medical technology company that has developed and patented...
Interim results Kista, Sweden, May 7, 2019 - Chordate Medical Holding AB's (publ) ("Chordate"), a specialty medtech company that focuses...
Interim results anticipated Q2 2019 Kista, Sweden, February 22, 2019 - Chordate Medical Holding AB's (publ) ("Chordate"), a specialty medtech...
Kista, August 14, 2018. Severn Healthcare Technologies Ltd. ("Severn") and Chordate Medical Holding AB (publ) have signed an exclusive distribution...
Chordate Medical Holding AB (publ) ("Chordate") has, through its subsidiary Chordate Medical AB, signed an agreement of co-ownership of a newly...
Data Anticipated Q4 2019 Kista, Sweden, May 08, 2018 - Chordate Medical Holding AB's (publ) ("Chordate"), a specialty medtech company that...

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the treatment Ozilia®, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia® in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact